Literature DB >> 25217863

Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Alexei F Kisselev1, Marcus Groettrup2.   

Abstract

Specialized variants of the constitutive 20S proteasome in the immune system like the immunoproteasomes and the thymoproteasome contain active site-bearing subunits which differ in their cleavage priorities and substrate binding pockets. The immunoproteasome plays a crucial role in antigen processing and for the differentiation of pro-inflammatory T helper cells which are involved in the pathogenesis of autoimmunity. Selective inhibitors of the immunoproteasome and constitutive proteasome have recently been generated which interfere with the development and progression of autoimmune diseases. Here we describe these inhibitors and their therapeutic potential as predicted from preclinical models.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217863      PMCID: PMC4564373          DOI: 10.1016/j.cbpa.2014.08.012

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  43 in total

1.  Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

Authors:  T Nazif; M Bogyo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Authors:  J Myung; K B Kim; K Lindsten; N P Dantuma; C M Crews
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 3.  β5t-containing thymoproteasome: specific expression in thymic cortical epithelial cells and role in positive selection of CD8+ T cells.

Authors:  Yousuke Takahama; Kensuke Takada; Shigeo Murata; Keiji Tanaka
Journal:  Curr Opin Immunol       Date:  2012-01-27       Impact factor: 7.486

4.  Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors.

Authors:  Simone Cenci; Laura Oliva; Fulvia Cerruti; Enrico Milan; Giada Bianchi; Mary Raule; Alexandre Mezghrani; Elena Pasqualetto; Roberto Sitia; Paolo Cascio
Journal:  J Leukoc Biol       Date:  2012-06-08       Impact factor: 4.962

5.  The antiviral immune response in mice devoid of immunoproteasome activity.

Authors:  Michael Basler; Ulrike Beck; Christopher J Kirk; Marcus Groettrup
Journal:  J Immunol       Date:  2011-10-19       Impact factor: 5.422

6.  Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection.

Authors:  Liping Tu; Chikako Moriya; Takashi Imai; Hidekazu Ishida; Kohhei Tetsutani; Xuefeng Duan; Shigeo Murata; Keiji Tanaka; Chikako Shimokawa; Hajime Hisaeda; Kunisuke Himeno
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

7.  Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

Authors:  Anne C Mirabella; Alexandre A Pletnev; Sondra L Downey; Bogdan I Florea; Tamer B Shabaneh; Matthew Britton; Martijn Verdoes; Dmitri V Filippov; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2011-05-27

8.  Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites.

Authors:  Paul P Geurink; Nora Liu; Michiel P Spaans; Sondra L Downey; Adrianus M C H van den Nieuwendijk; Gijsbert A van der Marel; Alexei F Kisselev; Bogdan I Florea; Herman S Overkleeft
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

9.  Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.

Authors:  Vinod Kasam; Na-Ra Lee; Kyung-Bo Kim; Chang-Guo Zhan
Journal:  Bioorg Med Chem Lett       Date:  2014-05-17       Impact factor: 2.823

10.  A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Authors:  Tony Muchamuel; Michael Basler; Monette A Aujay; Erika Suzuki; Khalid W Kalim; Christoph Lauer; Catherine Sylvain; Eileen R Ring; Jamie Shields; Jing Jiang; Peter Shwonek; Francesco Parlati; Susan D Demo; Mark K Bennett; Christopher J Kirk; Marcus Groettrup
Journal:  Nat Med       Date:  2009-06-14       Impact factor: 53.440

View more
  20 in total

Review 1.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

2.  Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Authors:  Marquicia R Pierce; Reeder M Robinson; Tannya R Ibarra-Rivera; Michael C Pirrung; Nathan G Dolloff; André S Bachmann
Journal:  Leuk Res       Date:  2019-11-12       Impact factor: 3.156

3.  A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors.

Authors:  Eva Shannon Schiffrer; Izidor Sosič; Andrej Šterman; Janez Mravljak; Irena Mlinarič Raščan; Stanislav Gobec; Martina Gobec
Journal:  Medchemcomm       Date:  2019-09-13       Impact factor: 3.597

4.  Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

Authors:  Wenhu Zhan; Pradeep K Singh; Yi Ban; Xiaoping Qing; Marie Dominique Ah Kioon; Hao Fan; Quanju Zhao; Rong Wang; George Sukenick; Jane Salmon; J David Warren; Xiaojing Ma; Franck J Barrat; Carl F Nathan; Gang Lin
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 8.039

5.  NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG.

Authors:  Margaret E Walker-Caulfield; Yong Guo; Renee K Johnson; Christina B McCarthy; Patrick D Fitz-Gibbon; Claudia F Lucchinetti; Charles L Howe
Journal:  J Neuroinflammation       Date:  2015-09-30       Impact factor: 8.322

6.  Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes.

Authors:  Juliane Liepe; Hermann-Georg Holzhütter; Elena Bellavista; Peter M Kloetzel; Michael P H Stumpf; Michele Mishto
Journal:  Elife       Date:  2015-09-22       Impact factor: 8.140

7.  Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.

Authors:  Bruno O Villoutreix; Abdel-Majid Khatib; Yan Cheng; Maria A Miteva; Xavier Maréchal; Joëlle Vidal; Michèle Reboud-Ravaux
Journal:  Oncotarget       Date:  2017-02-07

8.  The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.

Authors:  Giada Mondanelli; Elisa Albini; Maria T Pallotta; Claudia Volpi; Lucienne Chatenoud; Chantal Kuhn; Francesca Fallarino; Davide Matino; Maria L Belladonna; Roberta Bianchi; Carmine Vacca; Silvio Bicciato; Louis Boon; Giovanni Ricci; Ursula Grohmann; Paolo Puccetti; Ciriana Orabona
Journal:  Front Immunol       Date:  2017-04-13       Impact factor: 7.561

Review 9.  The 26S proteasome is a multifaceted target for anti-cancer therapies.

Authors:  Tatyana A Grigoreva; Vyacheslav G Tribulovich; Alexander V Garabadzhiu; Gerry Melino; Nickolai A Barlev
Journal:  Oncotarget       Date:  2015-09-22

10.  Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice.

Authors:  Julia Koerner; Thomas Brunner; Marcus Groettrup
Journal:  Oncotarget       Date:  2017-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.